AC Immune will acquire Affiris’ portfolio of therapeutics targeting alpha-synuclein (a-syn), which includes a vaccine candidate for the treatment of Parkinson’s disease.
In another blow to discovering a treatment for Alzheimer’s, Roche revealed that preliminary data from two clinical trials meant it was cancelling studies using crenezumab.
